Artículo
Immunotherapy for non-small cell lung cancer - Finally a hint of hope
Recondo, Gonzalo
; Galanternik, Fernando; Greco, Martín; de la Vega, Máximo; Cantón, E. Diaz; Valsecchi, Matías E.
Fecha de publicación:
06/2016
Editorial:
Bentham Science Publishers
Revista:
Reviews on Recent Clinical Trials
ISSN:
1574-8871
e-ISSN:
1876-1038,
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy. In this mini-review we will discuss the current applications and future consequences related this topic, paying special attention to the clinical studies that constitute the scientific evidence to supports its use.
Palabras clave:
IMMUNOTHERAPY
,
LUNG CANCER
,
NIVOLUMAB
,
PD-1
,
SQUAMOUS CELL CARCINOMA
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Recondo, Gonzalo; Galanternik, Fernando; Greco, Martín; de la Vega, Máximo; Cantón, E. Diaz; et al.; Immunotherapy for non-small cell lung cancer - Finally a hint of hope; Bentham Science Publishers; Reviews on Recent Clinical Trials; 11; 2; 6-2016; 87-92
Compartir
Altmétricas